Saadia Pharmaceuticals is committed to the development of innovative product candidates. Below are our product candidates and their status in our pipeline.
For the treatment of both core and associated symptoms of Autism Spectrum Disorder. One component of SP-101 is an FDA-safe New Therapeutic Entity that addresses restricted areas of interest/repetitive behaviors and associated irritability and constipation.
The second component is an FDA-approved pharmaceutical repurposed to address associated inattention, hyperactivity, and impulsivity.
The combination extended-release liquid formulation addresses social reciprocity by mitigating hyperfocusing on idiosyncratic stimuli while improving attention to relevant social cues.
SP-201 is an FDA-approved pharmaceutical that requires a further Phase 3 study showing superiority to its closest generic equivalent for a new indication: Treatment-Resistant Depression (TRD).
SP-201 would be the first FDA-approved oral treatment for TRD in the past 2 decades with low risk of weight gain, sedation, libido reduction, or extrapyramidal side effects compared to the only other oral FDA-approved medication alternative.
SP-301 was discovered from a Biblical fruit upon which organisms were not found to grow. Researchers at Saadia Pharmaceuticals identified and isolated the bactericidal eco-friendly components that destroy harmful algal blooms. Future studies will manufacture the ingredients to scale for treatment of larger bodies of water.
SP-401 (AI Ѱ™ ) is a virtual assistant for patients and medical professionals to facilitate evidence-based diagnostic, prognostic, and treatment decisions in Psychiatry. SP-401 incorporates the clinical acumen, knowledge, and expertise of a seasoned psychiatrist delivered through a machine learning algorithm to bring the highest level of care to all areas of the world.
Future studies will show superiority of SP-401 to psychiatric care currently provided by non-psychiatrists in terms of improved clinical outcomes.
© 2024 Saadia Pharmaceuticals, Inc. All Rights Reserved.
